Fatal interstitial pneumonitis related to rituximab-containing regimen

Clinical Lymphoma and Myeloma

Volumn 6, Issue 5, 2006, Pages 407-409

  Herishanu, Yair ^a   Polliack, Aaron ^a   Leider Trejo, Leonor ^a   Grieff, Yoel ^a   Metser, Ur ^a   Naparstek, Elizabeth ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti CD20 antibody; CHOP therapy; Non Hodgkin's lymphoma; Retreatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DRUG FATALITY; DYSPNEA; FOLLICULAR LYMPHOMA; HUMAN; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG SCINTISCANNING; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; THORAX RADIOGRAPHY;

EID: 33646565355     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.019     Document Type: Article

References (18)

1. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004; 55:477-503.
2. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94:2217-2224.
3. Byrd JC, Waselenko, JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17:791-795.
4. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348:2691-2694; discussion 2691-2694.
5. Westhoff TH, Jochimsen F. Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102:1930.
6. Lowndes S, Darby A, Mead G, et al. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13:1948-1950.
7. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 2002; 70:329.
8. Kanelli S, Ansell SM, Habermann TM, et al. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 2001; 42:1329-1337.
9. Burton C, Kuczmarski F. Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348:2690-2691; discussion 2690-2691.
10. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101:6-14.
11. Hainsworth JD, Litchy S, Lamb MR, et al. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Clin Lymphoma 2003; 4:36-42.
12. Swords R, Power D, Fay M, et al. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004; 77:103-104.
13. Alexandrescu DT, Dutcher JP, O'Boyle K, et al. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45:2321-2325.
14. Leon RJ, Gonsalvo A, Salas R, et al. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004; 79:949-953.
15. van der Kolk LE, Grillo-Lopez AJ, Baars JW et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115:807-811.
16. Selenko N, Maidic O, Draxier S, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001; 15:1619-1626.
17. Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis 1986; 133:321-340.
18. Malik SW, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996; 154:1851-1856.